Your browser doesn't support javascript.
loading
Antibody discovery identifies regulatory mechanisms of protein arginine deiminase 4.
Zhou, Xin; Kong, Sophie; Maker, Allison; Remesh, Soumya G; Leung, Kevin K; Verba, Kliment A; Wells, James A.
Afiliação
  • Zhou X; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
  • Kong S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Maker A; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Remesh SG; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
  • Leung KK; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
  • Verba KA; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
  • Wells JA; Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Nat Chem Biol ; 20(6): 742-750, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38308046
ABSTRACT
Unlocking the potential of protein arginine deiminase 4 (PAD4) as a drug target for rheumatoid arthritis requires a deeper understanding of its regulation. In this study, we use unbiased antibody selections to identify functional antibodies capable of either activating or inhibiting PAD4 activity. Through cryogenic-electron microscopy, we characterized the structures of these antibodies in complex with PAD4 and revealed insights into their mechanisms of action. Rather than steric occlusion of the substrate-binding catalytic pocket, the antibodies modulate PAD4 activity through interactions with allosteric binding sites adjacent to the catalytic pocket. These binding events lead to either alteration of the active site conformation or the enzyme oligomeric state, resulting in modulation of PAD4 activity. Our study uses antibody engineering to reveal new mechanisms for enzyme regulation and highlights the potential of using PAD4 agonist and antagonist antibodies for studying PAD4-dependency in disease models and future therapeutic development.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article